← Leaderboards
Gary W Reuther
H. Lee Moffitt Cancer Ctr & Res Inst
$4,321,756
Attributed
$4,321,756
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $485.8K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,321,756 · 3
By mechanism
R01$3,590,489 · 2
K01$731,267 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Fabiana Perna$1,525,955
- Mokenge P. Malafa$4,250,080
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularCellsEnvironmentLeadSignal TransductionLeukemiaLaboratoriesMutationProtein Tyrosine KinaseCancer CenterAffectPlayMediatingCell GrowthSuccessMouse ModelGeneticMyeloproliferative DiseaseOncogenesInnovationProteinsTherapeutic TargetBaseGenetic Screening
Grant awards (15)
Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms$464,330
R01 · FY2024 · HL · contact PI
Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms$477,968
R01 · FY2023 · HL · contact PI
Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms$483,261
R01 · FY2022 · HL · contact PI
Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms$485,801
R01 · FY2021 · HL · contact PI
Novel Myeloid Cell Transforming Properties of Interleukin-27 Receptor$315,962
R01 · FY2013 · CA · contact PI
Novel Myeloid Cell Transforming Properties of Interleukin-27 Receptor$336,129
R01 · FY2012 · CA · contact PI
Novel Myeloid Cell Transforming Properties of Interleukin-27 Receptor$336,129
R01 · FY2011 · CA · contact PI
Novel Myeloid Cell Transforming Properties of Interleukin-27 Receptor$346,525
R01 · FY2010 · CA · contact PI
Novel Myeloid Cell Transforming Properties of Interleukin-27 Receptor$344,384
R01 · FY2009 · CA · contact PI
Oncogenes involved in acute myeloid leukemia development$155,627
K01 · FY2007 · CA · contact PI
Oncogenes involved in acute myeloid leukemia development$154,961
K01 · FY2006 · CA · contact PI
Oncogenes involved in acute myeloid leukemia development$154,314
K01 · FY2005 · CA
Oncogenes involved in acute myeloid leukemia development$153,685
K01 · FY2004 · CA
Oncogenes involved in acute myeloid leukemia development$58,644
K01 · FY2003 · CA
Oncogenes involved in acute myeloid leukemia development$54,036
K01 · FY2003 · CA